Provided free of charge by a charity
Stability (i.e., disease progression stopped):
27% of patients stable for 4 months
22% stable for 6 months
19% stable for one to eight years
 No other drug has ever achieved this. For 16% of patients the drug has no effect i.e., non responders (Data source: Patients own monitoring reports observed by their neurologists).

11,000 doses, 120 years of accumulated patient-treatment, more than 25,000 datum points. This is profoundly more safety and clinical evidence of efficacy than any of the recently FDA approved drugs. Neuralzeta treatment continues and is ongoing.

Developed and supplied free of charge by a small informal charity on a first come first served basis with no exclusion criteria as a humanitarian endeavour when funding is available. The charity has never asked anyone for money at any time.

The objective is to get it approved and supplied at cost price..
This is in stark contrast to the recently approved ALS drugs: Toferson ($16,580 per month), Relyviro ($13,166 per month) and Edaravone ($14,083 per month) - none of which extend life. (Source: Biospace.com  April 25th 2023)

Kindly study `Important information`, in the black section at bottom of this page.